TessArae Partners with Israeli Testing Firm GGA to Design Cancer-Resequencing Chip
December 21, 2010
TessArae Partners with Israeli Testing Firm GGA to Design Cancer-Resequencing Chip
The partnership is one of several for TessArae, which has traditionally served the infectious disease-testing market, but has recently begun offering services to genetic disease-testing firms.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Israeli Testing Firm GGA Rolls out Array-Based Cancer Gene Resequencing Service
July 3, 2012 / BioArray News - Israeli Health Ministry to Subsidize Chromosomal Microarray Analysis for High-risk Pregnancies
May 8, 2012 / BioArray News - FDA Authorizes TessArae's RM-Flu Chip for Emergency H1N1 Testing
December 22, 2009 / BioArray News - TessArae Gets FDA Emergency Use Authorization for H1N1 Assay
December 21, 2009 / GenomeWeb Daily News - TessArae, GeneDx Develop Array-Based Tests for Noonan, Periodic Fever Syndromes
November 10, 2009 / BioArray News